BC-LI-0186

Overview

BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction ( IC 50 =46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS ( K d =42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > Aminoacyl-tRNA Synthetase

Product Information

• Catalog No.: HY-136265
• CAS No.: 695207-56-8
• Molecular Formula: C22H27N3O4S
• Molecular Weight: 429.53
• Purity: 99.37%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.84 mM); Clear solution
• Availability: In-stock

Source

Original product source